Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients

References

• Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011.
   Google Scholar
• Nahin RL. Estimates of pain prevalence and severity in adults: united States, 2012. J Pain. 2015;16:769–780.
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444–459.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Extended release (ER) and long-acting (LA) opioid analgesic Risk Evaluation and Mitigation Strategy (REMS). [ cited January 18, 2018]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM367697.pdf
   Google Scholar
• Opioid PMR Consortium. Structured discontinuation vs Continued therapy in suboptimal and optimal responders to high-dose long-term opioids for chronic pain. www.clinicaltrials.gov. Identifier: NCT02741076. [cited 2018 Jan 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02741076
   Google Scholar
• Boscarino JA, Hoffman SN, Han JJ. Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates. Subst Abuse Rehabil. 2015 Aug 19;6:83–91.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. Addiction. 2013 Apr;108(4):688–698.
   PubMed Web of Science ®Google Scholar
• Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015 Apr;156(4):569–576.
   PubMed Web of Science ®Google Scholar
• Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–2296.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Association; 2013.
   Google Scholar
• Cepeda MS, Fife D, Kihm MA, et al. Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse. Clin J Pain. 2014;30(12):1051–1056.
   PubMed Web of Science ®Google Scholar
• Katz N, Panas L, Kim M, et al. Usefulness of prescription monitoring programs for surveillance–analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006. Pharmacoepidemiol Drug Saf. 2010;19(2):115–123.
   PubMed Web of Science ®Google Scholar
• Chilcoat HD, Coplan PM, Harikrishnan V, et al. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). Drug Alcohol Depend. 2016 Aug;1(165):221–228.
   Web of Science ®Google Scholar
• Cepeda MS, Fife D, Chow W, et al. Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US. Drug Saf. 2012 Apr 1;35(4):325–334.
   PubMed Web of Science ®Google Scholar
• Postmarketing Requirements for the Class-Wide Extended-Release/Long-Acting Opioid Analgesics. [cited 2018 Jan 28]. Available from: http://wayback.archive-it.org/7993/20161022055348/http://www.fda.gov/Drugs/NewsEvents/ucm384489.htm
   Google Scholar
• Food and Drug Administration (FDA). Release from postmarketing requirement & new postmarketing requirement. [cited 2018 Jan 28]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM484415.pdf
   Google Scholar
• Opioid PMR Consortium. A prospective investigation of the risks of opioid misuse, abuse, and addiction among patients treated with extended-release/Long Acting (ER/LA) Opioids for the treatment of chronic pain www.clinicaltrials.gov. Identifier: NCT02751762. [cited 2018 Jul 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02751762?term=opioid+PMR&rank=5
   Google Scholar
• Opioid PMR Consortium. Incidence and predictors of opioid overdose and death in ER/LA opioid users as measured by diagnoses and death records. www.clinicaltrials.gov. Identifier: NCT02662153. [cited 2018 Jan 29]. Available from: https://clinicaltrials.gov/show/NCT02662153
   Google Scholar
• Opioid PMR Consortium. A quantitative study to assess the construct validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ). www.clinicaltrials.gov. Identifier: NCT02678507. [cited 2018 Jan 29]. Available from: https://clinicaltrials.gov/show/NCT02678507
   Google Scholar
• Opioid PMR Consortium. A qualitative study to assess the content validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ). www.clinicaltrials.gov. Identifier: NCT02660606. [cited 2018 Jan 29]. Available from: https://clinicaltrials.gov/show/NCT02660606
   Google Scholar
• Opioid PMR Consortium. Validation of PRISM-5-Op, measure of addiction to prescription opioid medication. www.clinicaltrials.gov. Identifier: NCT02660619. [cited 2018 Jan 29]. Available from: https://clinicaltrials.gov/show/NCT02660619
   Google Scholar
• Opioid PMR Consortium. Study to validate coded medical terms used to identify opioid-related overdose in databases used for PMR study 1B. www.clinicaltrials.gov. Identifier: NCT02667197. [cited 2018 Jan 29]. Available from: https://clinicaltrials.gov/show/NCT02667197
   Google Scholar
• Opioid PMR Consortium. An observational study to develop algorithms for identifying opioid abuse and addiction based on admin claims data. www.clinicaltrials.gov. Identifier: NCT02667262. [cited 2018 Jan 29]. Available from: https://clinicaltrials.gov/show/NCT02667262
   Google Scholar
• Opioid PMR Consortium. Cross-Sectional Study to Define and Validate “Doctor/Pharmacy Shopping” as Outcomes Suggestive of Abuse and/or Addiction. www.clinicaltrials.gov. Identifier: NCT02668549. [cited 2018 Jan 29]. Available from: https://clinicaltrials.gov/show/NCT02668549
   Google Scholar
• Opioid PMR Consortium. A survey to evaluate the relationship between Doctor/Pharmacy Shopping and outcomes suggestive of misuse, abuse and/or Diversion. www.clinicaltrials.gov. Identifier: NCT02667158. cited 2018 Jan 29. Available from: https://clinicaltrials.gov/show/NCT02667158
   Google Scholar
• Opioid PMR Consortium. Study to Evaluate the Relationship Between Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Medical Record Review. www.clinicaltrials.gov. Identifier: NCT02667210. cited 2019 Nov 2. Available from: https://clinicaltrials.gov/ct2/show/NCT02667210
   Google Scholar
• Windle M, Kogan SM, Lee S. Neighborhood serotonin transporter linked polymorphic region (5-HTTLPR) interactions for substance use from ages 10 to 24 years using a harmonized data set of African American children. Dev Psychopathol. 2016;28(2):415–431.
   PubMed Web of Science ®Google Scholar
• Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182–186.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Coplan PM, Kopper NW, et al. ER/LA opioid analgesics REMS: overview of ongoing assessments of its progress and its impact on health outcomes. Pain Med. 2017 Jan 1;18(1):78–85.
   PubMed Web of Science ®Google Scholar
• Divino V, Cepeda MS, Coplan P, et al. Assessing the impact of the extended-release/long-acting opioid analgesics risk evaluation and mitigation strategies on opioid prescription volume. J Opioid Manag. 2017;13(3):157–168.
   PubMedGoogle Scholar
• Bucher Bartelson B, Le Lait MC, Green JL, et al. Changes in misuse and abuse of prescription opioids following implementation of extended-release and long-acting opioid analgesic risk evaluation and mitigation strategy. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1061–1070.
   PubMed Web of Science ®Google Scholar
• Walker AM, Weatherby LB, Cepeda MS, et al. Possible opioid shopping and its correlates. Clin J Pain. 2017;33(11):976–982.
   PubMed Web of Science ®Google Scholar